Cytek Historical Balance Sheet

CTKB Stock

USD 4.13 0.09 2.13%

Trend analysis of Cytek Biosciences balance sheet accounts such as Other Current Liab of 23.6 M, Total Current Liabilities of 46.3 M or Total Stockholder Equity of 286.5 M provides information on Cytek Biosciences' total assets, liabilities, and equity, which is the actual value of Cytek Biosciences to its prevalent stockholders. By breaking down trends over time using Cytek Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cytek Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cytek Biosciences is a good buy for the upcoming year.

Cytek Biosciences Inventory

41.53 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

About Cytek Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cytek Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Cytek Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cytek Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cytek currently owns. An asset can also be divided into two categories, current and non-current.

Cytek Biosciences Balance Sheet Chart

At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5 M, whereas Total Assets are forecasted to decline to about 415.7 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Short Long Term Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of Cytek Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cytek Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Cytek Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cytek Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Most accounts from Cytek Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cytek Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5 M, whereas Total Assets are forecasted to decline to about 415.7 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	26.7M	26.2M	33.1M	23.6M
Total Assets	519.5M	494.5M	499.5M	415.7M

Other Current Liab Total Assets

Cytek Biosciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.97	0.91	0.99	0.93	0.97	0.9	0.85	-0.78	0.78	0.84	0.8	0.91	0.8	0.5	0.98	0.92	0.95	0.97	0.5	-0.55	0.93	0.93	0.95	-0.26	0.99
Other Current Liab	0.97		0.98	0.94	0.96	0.94	0.94	0.93	-0.62	0.66	0.92	0.64	0.96	0.86	0.38	0.91	0.97	0.95	0.95	0.47	-0.49	0.92	0.95	0.9	-0.17	0.94
Total Current Liabilities	0.91	0.98		0.89	0.97	0.91	0.97	0.98	-0.47	0.51	0.9	0.5	0.99	0.85	0.23	0.82	0.99	0.96	0.92	0.44	-0.54	0.93	0.94	0.88	-0.22	0.89
Total Stockholder Equity	0.99	0.94	0.89		0.95	0.97	0.89	0.84	-0.78	0.74	0.81	0.79	0.9	0.76	0.48	0.96	0.91	0.96	0.99	0.48	-0.68	0.92	0.92	0.99	-0.42	1.0
Other Liab	0.93	0.96	0.97	0.95		0.93	0.96	0.94	-0.58	0.58	0.88	0.61	0.96	0.76	0.35	0.85	0.98	0.97	0.98	0.36	-0.69	0.92	0.95	0.95	-0.39	0.95
Net Tangible Assets	0.97	0.94	0.91	0.97	0.93		0.89	0.86	-0.68	0.64	0.84	0.69	0.91	0.87	0.36	0.94	0.92	0.95	0.95	0.62	-0.66	0.91	0.9	0.96	-0.41	0.97
Property Plant And Equipment Net	0.9	0.94	0.97	0.89	0.96	0.89		0.95	-0.49	0.54	0.85	0.52	0.98	0.74	0.33	0.8	0.99	0.93	0.91	0.47	-0.56	0.96	0.98	0.88	-0.25	0.89
Current Deferred Revenue	0.85	0.93	0.98	0.84	0.94	0.86	0.95		-0.37	0.41	0.82	0.39	0.99	0.81	0.08	0.73	0.98	0.95	0.89	0.37	-0.55	0.91	0.88	0.84	-0.23	0.84
Net Debt	-0.78	-0.62	-0.47	-0.78	-0.58	-0.68	-0.49	-0.37		-0.96	-0.49	-1.0	-0.48	-0.38	-0.8	-0.88	-0.49	-0.59	-0.72	-0.25	0.34	-0.59	-0.6	-0.72	0.19	-0.78
Retained Earnings	0.78	0.66	0.51	0.74	0.58	0.64	0.54	0.41	-0.96		0.55	0.96	0.52	0.38	0.84	0.86	0.52	0.57	0.69	0.24	-0.14	0.62	0.65	0.65	0.06	0.74
Accounts Payable	0.84	0.92	0.9	0.81	0.88	0.84	0.85	0.82	-0.49	0.55		0.51	0.83	0.84	0.43	0.79	0.87	0.81	0.84	0.45	-0.44	0.74	0.9	0.78	-0.15	0.82
Cash	0.8	0.64	0.5	0.79	0.61	0.69	0.52	0.39	-1.0	0.96	0.51		0.51	0.38	0.81	0.89	0.52	0.61	0.74	0.25	-0.35	0.62	0.63	0.73	-0.19	0.79
Non Current Assets Total	0.91	0.96	0.99	0.9	0.96	0.91	0.98	0.99	-0.48	0.52	0.83	0.51		0.8	0.21	0.81	0.99	0.98	0.93	0.42	-0.56	0.96	0.93	0.89	-0.25	0.9
Non Currrent Assets Other	0.8	0.86	0.85	0.76	0.76	0.87	0.74	0.81	-0.38	0.38	0.84	0.38	0.8		0.07	0.75	0.81	0.81	0.75	0.66	-0.41	0.72	0.74	0.72	-0.16	0.76
Other Assets	0.5	0.38	0.23	0.48	0.35	0.36	0.33	0.08	-0.8	0.84	0.43	0.81	0.21	0.07		0.6	0.26	0.24	0.43	0.17	-0.09	0.33	0.5	0.42	0.0	0.48
Cash And Short Term Investments	0.98	0.91	0.82	0.96	0.85	0.94	0.8	0.73	-0.88	0.86	0.79	0.89	0.81	0.75	0.6		0.82	0.87	0.93	0.5	-0.5	0.85	0.86	0.91	-0.25	0.96
Net Receivables	0.92	0.97	0.99	0.91	0.98	0.92	0.99	0.98	-0.49	0.52	0.87	0.52	0.99	0.81	0.26	0.82		0.97	0.94	0.46	-0.61	0.95	0.96	0.91	-0.3	0.92
Good Will	0.95	0.95	0.96	0.96	0.97	0.95	0.93	0.95	-0.59	0.57	0.81	0.61	0.98	0.81	0.24	0.87	0.97		0.97	0.41	-0.67	0.94	0.9	0.95	-0.38	0.96
Common Stock Total Equity	0.97	0.95	0.92	0.99	0.98	0.95	0.91	0.89	-0.72	0.69	0.84	0.74	0.93	0.75	0.43	0.93	0.94	0.97		0.36	-0.69	0.91	0.92	0.98	-0.41	0.99
Common Stock Shares Outstanding	0.5	0.47	0.44	0.48	0.36	0.62	0.47	0.37	-0.25	0.24	0.45	0.25	0.42	0.66	0.17	0.5	0.46	0.41	0.36		-0.28	0.51	0.51	0.45	-0.22	0.48
Non Current Liabilities Total	-0.55	-0.49	-0.54	-0.68	-0.69	-0.66	-0.56	-0.55	0.34	-0.14	-0.44	-0.35	-0.56	-0.41	-0.09	-0.5	-0.61	-0.67	-0.69	-0.28		-0.55	-0.54	-0.78	0.94	-0.67
Inventory	0.93	0.92	0.93	0.92	0.92	0.91	0.96	0.91	-0.59	0.62	0.74	0.62	0.96	0.72	0.33	0.85	0.95	0.94	0.91	0.51	-0.55		0.94	0.9	-0.26	0.92
Other Current Assets	0.93	0.95	0.94	0.92	0.95	0.9	0.98	0.88	-0.6	0.65	0.9	0.63	0.93	0.74	0.5	0.86	0.96	0.9	0.92	0.51	-0.54	0.94		0.9	-0.25	0.92
Other Stockholder Equity	0.95	0.9	0.88	0.99	0.95	0.96	0.88	0.84	-0.72	0.65	0.78	0.73	0.89	0.72	0.42	0.91	0.91	0.95	0.98	0.45	-0.78	0.9	0.9		-0.55	0.99
Total Liab	-0.26	-0.17	-0.22	-0.42	-0.39	-0.41	-0.25	-0.23	0.19	0.06	-0.15	-0.19	-0.25	-0.16	0.0	-0.25	-0.3	-0.38	-0.41	-0.22	0.94	-0.26	-0.25	-0.55		-0.42
Net Invested Capital	0.99	0.94	0.89	1.0	0.95	0.97	0.89	0.84	-0.78	0.74	0.82	0.79	0.9	0.76	0.48	0.96	0.92	0.96	0.99	0.48	-0.67	0.92	0.92	0.99	-0.42

Click cells to compare fundamentals

Cytek Biosciences Account Relationship Matchups

Cytek Biosciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	220.0M	463.7M	519.5M	494.5M	499.5M	415.7M
Other Current Liab	15.5M	19.2M	26.7M	26.2M	33.1M	23.6M
Total Current Liabilities	26.5M	32.2M	49.0M	56.2M	67.7M	46.3M
Total Stockholder Equity	(16.0M)	406.5M	425.3M	393.1M	395.7M	286.5M
Property Plant And Equipment Net	2.1M	5.9M	27.6M	29.3M	28.1M	17.2M
Current Deferred Revenue	4.3M	7.1M	13.0M	22.7M	25.5M	13.9M
Net Debt	(162.5M)	(364.6M)	(278.5M)	(153.2M)	(91.2M)	(95.7M)
Retained Earnings	(22.6M)	(18.2M)	(17.0M)	(29.2M)	(35.2M)	(37.0M)
Accounts Payable	2.9M	3.0M	4.8M	3.0M	5.5M	4.0M
Cash	165.2M	364.6M	296.6M	167.3M	98.7M	93.8M
Non Current Assets Total	11.4M	31.6M	65.5M	102.4M	103.1M	58.0M
Non Currrent Assets Other	1.1M	1.7M	1.4M	1.8M	4.8M	5.0M
Other Assets	8.5M	10.9M	21.8M	1.0	1.15	1.09
Cash And Short Term Investments	165.2M	364.6M	341.1M	262.4M	277.9M	264.3M
Net Receivables	18.1M	29.8M	48.9M	56.1M	60.6M	42.4M
Liabilities And Stockholders Equity	220.0M	463.7M	519.5M	494.5M	499.5M	415.7M
Non Current Liabilities Total	209.5M	24.7M	44.9M	45.2M	36.1M	60.2M
Inventory	23.0M	32.2M	48.2M	60.9M	43.9M	41.5M
Other Current Assets	2.3M	4.9M	17.9M	12.7M	14.1M	9.6M
Other Stockholder Equity	(194.3M)	423.6M	442.9M	423.4M	430.8M	266.2M
Total Liab	236.0M	56.9M	93.9M	101.4M	103.8M	93.9M
Net Invested Capital	(13.3M)	406.5M	427.6M	395.3M	401.4M	288.9M
Property Plant And Equipment Gross	2.1M	7.7M	27.6M	35.2M	36.8M	20.3M
Total Current Assets	208.6M	432.1M	454.0M	392.1M	396.4M	357.7M
Accumulated Other Comprehensive Income	65K	897K	(697K)	(1.3M)	16K	16.8K
Capital Stock	23K	126K	135K	131K	129K	103.6K
Non Current Liabilities Other	11.7M	14.9M	29.5M	18.9M	11.4M	18.5M
Net Working Capital	182.1M	399.9M	405.0M	335.8M	328.8M	311.4M
Short Term Debt	2.8M	15.3M	12.6M	3.0M	3.5M	3.3M
Intangible Assets	274K	4.7M	4.3M	23.1M	20.1M	21.1M
Common Stock	23K	126K	135K	131K	129K	103.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:

How To Invest In Cytek

Details

Is Cytek Stock a good investment?

Details

What is Cytek Biosciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.735

Earnings Share

(0.05)

Revenue Per Share

1.535

Quarterly Revenue Growth

(0.01)

Return On Assets

(0.03)

The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytek Historical Balance Sheet

Cytek Biosciences Inventory

41.53 Million

About Cytek Balance Sheet Analysis

Cytek Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Short Long Term Debt

Cytek Biosciences balance sheet Correlations

Cytek Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cytek Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Stockholder Equity	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Current Liabilities
Net Receivables	+ 0.99	Total Current Liabilities
Common Stock Total Equity	+ 0.99	Total Stockholder Equity

Cash	- 1.0	Net Debt
Retained Earnings	- 0.96	Net Debt
Cash And Short Term Investments	- 0.88	Net Debt
Other Assets	- 0.8	Net Debt
Other Stockholder Equity	- 0.78	Non Current Liabilities Total
Net Invested Capital	- 0.78	Net Debt